July 26, 2022
July 26, 2022: Guelph, ON – Nutrasource Pharmaceutical and Nutraceutical Services, a global full-service contract research organization (CRO), announced today that Kelai Pharmaceutical LLC, a US-based firm with expertise and technology associated with the kava plant and its derivatives, has chosen Nutrasource to support and strategically manage its early-stage drug development program.
“Navigating the regulatory pathway for a new drug is no simple task,” notes Dr. Jacqueline Jacques, CEO, Kelai Pharmaceutical. “Kelai is happy to have an FDA regulatory partner with significant expertise in both natural compounds and pharmaceuticals to support us in plotting this course. This will let us be laser-focused on the most important tasks – minimizing our risk and optimizing our efforts from the earliest stages of development.”
Botanicals represent unique pharmaceutical opportunities because they start out as very complex endogenous compounds, and many different aspects of the plant might produce the eventual drug candidate. Navigating this journey in a very targeted manner is mission critical. Although the medicinal properties of botanicals are often well known, they have not been developed in a pharmaceutical context, which is both a challenge and an opportunity.
“Nutrasource’s longstanding strategic positions in both nutrition and pharmaceutical scientific solutions were key factors in Kelai’s decision making process,” says William Rowe, President, and CEO of Nutrasource. “We are delighted to be serving Dr. Jacques and her team in this capacity, bringing cutting edge botanicals and related technology down the pharmaceutical pathway.”
- Learn more about Nutrasource Drug Development Strategies
About Nutrasource Pharmaceutical and Nutraceutical Services Inc.
Nutrasource is a leading nutraceutical and pharmaceutical life sciences company that brings together the strategy, expertise and services required to help clients commercialize health and wellness products with strong science and regulatory confidence. Our unique offering of clinical trial management, strategic and regulatory consulting services along with a state-of-the-art clinical trial site has been developed with one goal in mind – your success in the global marketplace. We also offer a series of third-party certification programs focused on natural health ingredients such as omega-3s (IFOS™), probiotics (IPRO™), non-GMO (IGEN™), and CBD (ICAP™). All of our groups work closely with our research and development team, which is developing timely products such as POC (Point-of-Care) technology and a RWD (Real World Data) system for consumer information collection. www.nutrasource.ca
About Kelai Pharmaceutical
Kelai Pharmaceutical is a U.S.-based pharmaceutical company that brings together powerful natural molecules with patented Advanced Drug Delivery technology to create safe and effective new treatments for addiction and mental health disorders. As a strategic joint venture created by Thorne HealthTech and Mycrodose Therapeutics, Kelai leverages the resources, intellectual property, and human capital of both companies to focus on lean drug development and innovation for conditions with unmet or underserved needs.